IMCR
NASD Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh$29.71 ↑ +0.00 (+0.00%) Trading Up from the previous close of $29.71, $1.08 below the day’s high of $30.79
- YTD change
- -14.41%
- vs 20-day SMA
- -8.63%
- vs 200-day SMA
- -7.78%
Price ranges
Price & Performance
-2.23 (-6.98%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 61.4% away from all-time highs of $76.98
- IMCR is down 14% since the beginning of the year
- IMCR is down 16% over the past 12 months
- IMCR is down 20% over the past 1 month
- 16% of all IMCR investors are betting against IMCR
IMCR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -12.6%.
- Previous minute
- +$0.00
- Last hour
- +$0.12
- Last 5 days
- -5.05%
- vs 8-day SMA
- -4.27%
No alerts for IMCR in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
